BCRF1 antagonists for treating epstein-barr virus infections

Chemistry: molecular biology and microbiology – Spore forming or isolating process

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

5303873, 53038823, 5303883, 53038885, 5303892, 4352402, 4241411, 4241581, C12N 512, C07K 1608, A61K 39395

Patent

active

057563420

ABSTRACT:
A method of treating EBV infections is provided. The method comprises administering an effective amount of an monoclonal antibody antagonist to the EBV protein, BCRF1. Preferably, the antagonist is a blocking monoclonal antibody specific for BCRF1, or a fragment or binding composition derived therefrom.

REFERENCES:
patent: 5231012 (1993-07-01), Mosmann et al.
Seaver, Genetic Engineering News 14:10,21 1994.
Hams et al., Tibtech 11:42-44, 1993.
Casali et al., Science 234:476-479, 1986.
Baer et al., "DNA seuence and expression of the b95-8 Epstein-Barr virus genome," Nature 310:207-211 (Jul. 1984).
Bean et al., "Interleukin 10 protects mice against staphylococcal enterotoxinB-induced lethal shock," Infection and Immuity 61(10):4937-4939 (1993).
de Waal Malefyt et al., "Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes," J. Exp. Med. 174:1209-1220 (1991).
Fiorentino et al., "Two types of mouse T helper cell IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones," Journal of Experimental Medicine 170:2081-2095 (1989).
Fiorentino et al,. "IL-10 inhibits cytokine production by activated macrophages," The Journal of Immunology 147(11):3815-3822 (1991).
Go et al., "Interleukin 10, a novel B cell stimulatory factor: Unresponsiveness of X chromosome-linked immunodeficiency B cells," Journal of Experimental Medicine 172(6):1625-1631 (1990).
Hirsch, "Herpesvirus infections," Scientific American Medicine 2(Chapter XXVI):1-11 (Oct. 1992).
Horowitz et al., "Autocrine growth inhibition of a cloned line of helper T cells," Proc. Natl. Acad. Sci. USA 83:1886-1890 (1986).
Howard et al., "Interleukin 10 protects mice from lethal endotoxemia," J. Exp. Med. 177:1205-1211 (1993).
Hsu et al., "differential effects of IL-4 and IL-10 on IL-2 induced IFN-.gamma. synthesis and lumphokine-activated killer activity," J. of Immunol. 6:663-663 (1992).
Hsu, "Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1," Science 250:830-832 (Nov. 1990).
Hudson et al., "The short unique region of the B95-8 Epstein-Barr virus genome," Virology 147:81-98 (1985).
International Search Report from corresponding application (Jul. 1991).
Joakim Dillner et al., "The Epstein-Barr virus proteins," Advances in Cancer Research 50:95-158 (1988).
Kohler et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature 256:495-497 (Aug. 1975).
Marchant et al., "Interleukin-10 controls interferon-.gamma. and tumor necrosis factor production during experimental endotoxemia," Eur. J. Immunol. 24:1167-1171 (1994).
McDevitt, "The molecular basis of autoimmunity," Clinical Research 34:163-175 (1985).
Moore et al., "Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI," Science 248:1230-1234 (Jun. 1990).
Schooley et al., "Epstein-Barr virus (infectious mononucleosis)," Principles and Practice of Infectious Disease, second ed., John Wiley & Sons, Chapter 126, pp. 971-979 (1985).
Swaminathan et al., "Epstein-Barr virus recombinants with specifically mutated BCRF1 genes," Journal of Virology 67(2):7406-7413 (1993).
Thorley-Lawson, "Immunological responses to Epstein-Barr virus infection and the pathogenesis of EBV-induced diseases," Biochimica et Biophysical Acta, 948:263-286 (1988).
Tosato, "The Epstein-Barr virus and the immune system," Advances in Cancer Research, 49:75-125 (1987).
Vieiera et al., "Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: Homology to Expstein-Barr virus open reading frame BCRF1," Proc. Natl. Acad. Sci. USA 88:1172-1176 (1991).
von Heijne, "A new method for predicting signal sequence cleavage sites," Nucleic Acids Research 14(11):4683-4690 (1986).
Waldmann, "Monoclonal antibodies in diagnosis and therapy," Science, 252:1657-1662 (Jun. 1991).
Albert Zlotnik, et al., "Effects of IL-10 in Lipopolysaccharide- and Superantigen-Induced Lethal Shock in Vivo", Molecular Biology Intelligence Unit - Interleukin 10, Chapter 13, pp. 121-126 (1995).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

BCRF1 antagonists for treating epstein-barr virus infections does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with BCRF1 antagonists for treating epstein-barr virus infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and BCRF1 antagonists for treating epstein-barr virus infections will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1959140

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.